Talk:Insulin secretion
Discussion page·3 threads·no archives
This is the discussion page for the article Insulin secretion. It is for improving the article: sources, wording, structure, scope and titles. It is not a general discussion forum about the subject, and it is not a place to ask for advice — see Project:Medical disclaimer.
Trigger versus amplification framingResolved
Strongly support keeping the trigger/amplify distinction in the lead. It is the one idea that makes the hypoglycaemia difference between drug classes obvious, and readers arriving from the agonist articles need it early. — BetaCellBoyd (talk) 09:18, 20 February 2026 (UTC)
Agreed. I moved it up from the third paragraph to the second. ✓ Done — Peptide_Pete (talk) 11:55, 20 February 2026 (UTC)
Beta-cell mass at diagnosis: the number keeps changing
Different sources give different figures for the fraction of beta-cell function lost at diagnosis, from about a third to about four fifths. The article now avoids a single number, which I think is right, but should it say why the estimates disagree? — CitationChaser (talk) 13:05, 24 April 2026 (UTC)
Because functional and morphometric estimates measure different things and neither is measurable prospectively in living people. I have added a clause to that effect. — BetaCellBoyd (talk) 16:40, 24 April 2026 (UTC)
That clause is a good addition. It converts an apparent contradiction into an explained one. — HedgeHedda (talk) 09:12, 25 April 2026 (UTC)
Which secretion index should the article recommend?Done
Should the measurement section say which index a reader should prefer? — HOMA_Hettie (talk) 10:30, 2 June 2026 (UTC)
No. Recommending is not our function. Describing what each index measures and warning that they are not interchangeable is. — NPOV_Nadia (talk) 12:44, 2 June 2026 (UTC)
Fair. The non-interchangeability sentence covers the practical need. ✓ Done — HOMA_Hettie (talk) 15:02, 2 June 2026 (UTC)